AF
LEXX icon

Allworth Financial’s Lexaria Bioscience LEXX Stock Holding History

Allworth Financial’s Portfolio LEXX Stock Details LEXX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q3 		– Sell
-89
Closed -$243 – 3794
2024
Q2 		$243 Hold
89
– – ﹤0.01% 3523
2024
Q1 		$324 Hold
89
– – ﹤0.01% 3380
2023
Q4 		$112 Buy
+89
New +$115 ﹤0.01% 3343

Other funds holding LEXX

ICM
Invenomic Capital Management Boston, Massachusetts $2.18B AUM 0.03% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
G
GenTrust Miami, Florida $2.34B AUM 18.43% 1-Year Est. Return
RJFSA
Raymond James Financial Services Advisors St. Petersburg, Florida $75.1B AUM 31.89% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
WG
Welch Group Birmingham, Alabama $2.93B AUM 27.62% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
XT
XTX Topco George Town, Cayman Islands $5.75B AUM 30.56% 1-Year Est. Return

Allworth Financial's LEXX Position: Q3 2024 in Review

Allworth Financial sold out of Lexaria Bioscience (LEXX) in Q3 2024, closing a stake of 89 shares — an estimated $243 sold.

Allworth Financial first reported a position in LEXX in Q4 2023 and held it in 3 quarters. The position peaked at $324 in Q1 2024. 27 funds tracked by Wall St. Rank hold LEXX as of Q3 2024.

  • Allworth Financial reported no remaining Lexaria Bioscience position as of Q3 2024 after selling out during the quarter.
  • Allworth Financial sold 89 Lexaria Bioscience shares in Q3 2024, an estimated $243.
  • Allworth Financial first reported a position in Lexaria Bioscience in Q4 2023 and held it in 3 quarters.
  • Allworth Financial's Lexaria Bioscience position peaked at $324 in Q1 2024.
  • 27 funds tracked by Wall St. Rank held Lexaria Bioscience as of Q3 2024.

Based on Allworth Financial's 13F filing for Q3 2024, filed 23 Oct 2024.